近日，齐鲁晚报·齐鲁壹点记者从信用中国（江西）获悉，江西新瑞丰生化股份有限公司因在产品中掺杂、掺假，以假充真，以次充好，或者以不合格产 品冒充合格产品的行为，被新干县市场监督管理局行政处罚。1、责令停止生产销售不合格的含氨基酸水溶肥料；2、处罚款902889元；3、没收违法所得 90271.9元；以上两项合计金额993160.9元。 | 信用用系(x) | | | | --- | --- | --- | | WWW.CREDITJX.GOV.CN | | | | 信用信息 统一社会信用代码 | 站内文章 | | | Ｑ ■输入主体名称或者统一社会信用代码 搜索 | | | | the later the could stime aller aller like interest -4-4-8000 | | NOW of 1 1-4 | | 原因為留守 。 因和中 因意和 | | | --- | --- | | 行政相对人名称: | 江西新瑞丰生化股份有限公司 | | 行政处罚决定书文号: | 干市监处罚 < 2025> 135号 | | · Bank Links (1) | 在产品中排杂、抄假,以假充真,以次 ...

Core Insights - Fuxiang Pharmaceutical reported a revenue of 769 million yuan for the first three quarters of 2025, focusing on the synergistic development of its three core businesses: pharmaceutical manufacturing, new energy lithium battery materials, and synthetic biological microbial proteins [1] R&D Foundation - In the pharmaceutical manufacturing sector, the company is enhancing product potential through green alternatives and process optimizations, leading to a continuous decrease in production costs [2] - The company has achieved a production capacity of 8,000 tons of vinyl carbonate (VC) and 3,700 tons of fluorinated ethylene carbonate (FEC) in its new energy segment, benefiting from a recovering market for electrolyte additives, with prices rising over 20% month-on-month [2] Marketing Expansion - Fuxiang Pharmaceutical is strengthening strategic partnerships with core customers and expanding into international markets, particularly in the synthetic biological microbial protein sector [4] - The establishment of the Weiran Alliance in Shanghai aims to commercialize new protein products and has attracted several international brands as initial members [4] International Market Development - The company has secured a patent in South Korea for its application of short-handled fungus in producing mycelium protein, laying a solid foundation for entering the East Asian market [5] - Fuxiang Pharmaceutical has established a subsidiary in Singapore to focus on the development and sales of microbial protein consumer products, accelerating its overseas market expansion [5][6] Future Outlook - The company plans to continue investing in R&D innovation, enhancing marketing networks, and deepening collaborative innovation with strategic partners to activate new growth momentum [6]

Core Insights - Fuxiang Pharmaceutical reported a revenue of 769 million yuan for the first three quarters of 2025, highlighting its differentiated high-quality development path in the competitive chemical pharmaceutical sector [1] Group 1: R&D and Business Segments - The company is focusing on three core business areas: pharmaceutical manufacturing, new energy lithium battery materials, and synthetic biological microbial proteins, aiming to build a diversified strategic framework [2] - In pharmaceutical manufacturing, Fuxiang is enhancing product potential through green alternatives and process optimizations, leading to a continuous reduction in production costs and reinforcing its competitive position in the active pharmaceutical ingredient market [2] - The new energy segment has established a production capacity of 8,000 tons of vinyl carbonate (VC) and 3,700 tons of fluorinated ethylene carbonate (FEC), benefiting from a recovering market for electrolyte additives, with prices rising over 20% month-on-month [2] Group 2: Marketing and Market Expansion - Fuxiang is enhancing its market presence by deepening strategic partnerships with core customers and expanding into key international markets, thereby creating new growth opportunities [4] - The company has established the Weiran Alliance in Shanghai to facilitate the commercialization of its new protein products, attracting international brands as initial members [4] - Fuxiang is actively expanding into the East Asian market, having secured a patent in South Korea for its production technology, and is developing a subsidiary in Singapore to accelerate overseas market penetration [5] Group 3: Future Outlook - The company plans to continue strengthening its R&D investments, enhancing marketing networks, and fostering collaborative innovation with strategic partners to drive the application of microbial protein technology across various sectors [6]

Core Viewpoint - Fujian Pharmaceutical Co., Ltd. has received approval for its amino acid water-soluble fertilizer product, allowing it to be sold in the domestic market [1] Group 1 - Fujian Pharmaceutical's subsidiary, Jiangxi Fujian Biotechnology Co., Ltd., is responsible for the newly approved fertilizer product [1] - The product has been granted a registration certificate by the National Agricultural and Rural Affairs Ministry's Fertilizer Registration Review Committee, with the registration number: Agricultural Fertilizer (2025) Approval No. 21015 [1] - This approval marks a significant milestone for the company, enabling it to expand its product offerings in the agricultural sector [1]